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Abstract
Purpose—Stemming from breast density notification legislation in Massachusetts effective 
2015, we sought to develop a collaborative evidence-based approach to density notification that 
could be used by practitioners across the state. Our goal was to develop an evidence-based 
consensus management algorithm to help patients and health care providers follow best practices 
to implement a coordinated, evidence-based, cost-effective, sustainable practice and to standardize 
care in recommendations for supplemental screening.
Methods—We formed the Massachusetts Breast Risk Education and Assessment Task Force 
(MA-BREAST) a multi-institutional, multi-disciplinary panel of expert radiologists, surgeons, 
primary care physicians, and oncologists to develop a collaborative approach to density 
notification legislation. Using evidence-based data from the Institute for Clinical and Economic 
Review (ICER), the Cochrane review, National Comprehensive Cancer Network (NCCN) 
guidelines, American Cancer Society (ACS) recommendations, and American College of 
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Radiology (ACR) appropriateness criteria, the group collaboratively developed an evidence-based 
best-practices algorithm.
Results—The expert consensus algorithm uses breast density as one element in the risk 
stratification to determine the need for supplemental screening. Women with dense breasts and 
otherwise low risk (<15% lifetime risk), do not routinely require supplemental screening per the 
expert consensus. Women of high risk (>20% lifetime) should consider supplemental screening 
MRI in addition to routine mammography regardless of breast density.
Conclusion—We report the development of the multi-disciplinary collaborative approach to 
density notification. We propose a risk stratification algorithm to assess personal level of risk to 
determine the need for supplemental screening for an individual woman.
Background
Legislation regarding breast density notification is rapidly being implemented across the 
country. As of January 2015, 21/50 (42%) states have adopted legislation that requires 
patients undergoing screening mammography to be informed of their mammographic breast 
density as determined by the interpreting radiologist. In addition, federal legislation has been 
introduced, but is currently not active. State laws have been driven primarily by patient and 
grassroots advocacy organizations (e.g., http://www.areyoudenseadvocacy.org/) and differ 
in their implementation requirements. At a minimum, most laws require that the woman be 
informed that breast density may be a risk factor for breast cancer, may make cancer 
detection more difficult, and that additional supplemental screening may be indicated.
Further complicating the issue, most states have not mandated insurance coverage for 
supplemental screening tests [1]. This lack of coordinated coverage may increase health care 
disparities if the ability to self-pay for additional evaluation influences patient management.
There are currently no evidence-based recommendations for implementation of this 
legislation or to aid with patient and provider decision-making. Thus, the use of 
supplemental screening methods, particularly ultrasound, has varied among institutions, and 
even more widely among states. In the first year after adopting density notification 
legislation in Connecticut, some clinicians referred nearly all patients with dense breasts for 
supplemental screening ultrasound, while others referred none [2]. Further, only 45% of 
patients who received initial screening ultrasound actually returned for repeat screening 
ultrasound although they continued with annual mammography [2]. The lack of consensus, 
the subjective assessment of mammographic density, and the insufficient scientific evidence 
supporting widespread supplemental screening in women at average risk may be confusing 
to women and primary care providers.
The need for consensus and the formation of MA-BREAST
We formed the Massachusetts Breast Risk Education and Assessment Task Force (MA-
BREAST) workgroup comprised of radiologists, breast surgeons, internal medicine 
specialists, and oncologists from academic and community based practices with the goals of 
[1] educating patients and physicians about the benefits, limitations, and risks of 
supplemental breast cancer screening and [2] developing a model of evidence-based 
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sustainable consensus recommendations for use of supplemental screening in dense breasts 
(Figure 1).
We used an evidence-based review of the literature, including the Institute for Clinical and 
Economic Review (ICER) report (together with the New England Comparative 
Effectiveness Public Advisory Council (CEPAC) and California Technology Assessment 
Forum (CTAF) reviews), the Cochrane review, the National Comprehensive Cancer 
Network (NCCN) guidelines, American Cancer Society (ACS) recommendations, the 
American College of Radiology appropriateness criteria, and the California Breast Density 
Information Group (CDBIG) algorithm [3–11]. We summarize the evidence and present our 
algorithm in this paper.
The risk of breast density and the goal of BI-RADS density classification
Mammographic breast density is an estimate of the amount of radio-opaque tissue (stromal 
and epithelial elements) relative to radio-lucent fatty tissue. Mammographic density does not 
correlate with physical exam [12–13]. When interpreting a mammogram, the radiologist 
classifies density using a subjective scale from the Breast Imaging Reporting and Data 
System (BI-RADS) as “almost entirely fat”, “scattered fibroglandular density”, 
“heteregeneously dense”, or “extremely dense” [14]. Although not in routine use, automated 
methods of density determination are also available. Dense breasts, defined as 
heterogeneously dense or extremely dense, are common, found in nearly 50% of the 
screening population. An estimated 1,250,585 women per year will require density 
notification in New England alone if legislation continues across the region [5]. This 
subjective assessment has limited intra- and inter-reader agreement, especially for the 
middle two density categories that may affect whether a woman is classified as “dense” or 
“not dense” [14–16]. Additionally, density is influenced by factors such as hormone status 
and weight changes [17]. Thus, a woman may be classified as having dense breasts one year, 
but not another (Figure 2).
Breast density primarily affects mammographic sensitivity by a masking phenomenon, 
where dense tissue may obscure an underlying malignancy [18–20]. Digital mammography 
has helped improve the sensitivity in dense breasts relative to fatty breasts [21, 22], however 
masking remains a challenge. Recent data suggests screening digital breast tomosynthesis 
may detect malignancies not seen on 2D mammography in women with dense breasts [23–
24].
Dense breast tissue is also an independent risk factor for breast cancer with evidence 
suggesting that women with heterogeneously dense breasts have a 1.2-fold increased risk of 
breast cancer compared to the average patient’s risk, and women with extremely dense 
breasts have a 2.1-fold increased risk [25–26]. These more reasonable assessments differ 
from often quoted relative risks of 4–6x which are derived from comparing the densest 
breasts (10% of the population) with those with almost completely fatty breasts (10%) [18, 
27–28].
Freer et al. Page 3
Breast Cancer Res Treat. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Massachusetts Legislation Experience
In July 2014, breast density notification legislation was passed in Massachusetts [29]. When 
the Massachusetts Radiological Society became aware of potential legislation, introduced by 
lay activists, a coalition of academic and community radiologists engaged the state’s 
legislative leadership. Initially, the coalition expressed reservations about the lack of 
insurance coverage and scientific evidence for widespread ultrasound screening and the 
subjective and unreliable nature of density measurement. However, as it became clear the 
legislation would pass, the coalition focused on ensuring the wording of the law would 
promote patient care and education, improved patient-physician communication, and cost-
effective, evidence-based decision-making. Thus, the law encourages consultation between 
the patient and her referring provider to maximize education and decide about additional 
screening, but does not recommend or even mention specific supplemental screening 
modalities.
The group drafted a sample notification letter for patients that emphasizes that dense tissue 
is normal and common, and that density should be considered with other known breast 
cancer risk factors in determining overall risk status and deciding about supplemental 
screening (eTable 1). The use of a common educational letter for all patients undergoing 
mammography, with an individualized density statement, satisfies the legal notification 
requirements, and avoids falsely alarming women with dense breasts or falsely reassuring 
those without dense breasts who might otherwise be at high risk. The letter includes a link to 
an educational website (http://breast.massrad.org).
The coalition was unsuccessful in having the law mandate insurance coverage for the 
additional screening. Thus, additional screening may require self-pay, a potential burden for 
women with high-deductible insurance plans.
Screening modalities: benefits and limitations
Screening Mammography
Mammography, although imperfect, remains the only screening modality proven to 
demonstrate a decrease in breast cancer mortality [30]. Early detection by mammography 
yields a mortality reduction from breast cancer between 15–30% based on several large 
randomized controlled trials with 1–2 decades of follow-up [31–32]. Moreover, earlier 
cancer detection may limit the need for mastectomy, axillary dissection, and chemotherapy. 
At the low doses used today, the radiation risks are small to negligible in the screening age 
population. The mammographic cancer detection rate is 4–5 / 1000 in the average 
population. False positives are an important concern, with the mammographic recall rate (for 
additional imaging and/or biopsy) approximating 10% [3, 33]. For women who undergo 10 
years of consecutive screening, approximately half will be called back for additional 
imaging at least once [34]. However, the positive predictive value for findings that undergo 
biopsy (PPV3) based on screening mammogram is moderately high, approximately 25–35% 
[3, 33]. For women with dense breasts, digital mammography has higher sensitivity than 
film-screen, approximating the sensitivity of fatty breasts, and is preferred. However, even 
in women with fatty breasts, mammography (digital or film-screen) misses approximately 
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12–22% of breast cancers [3,21, 35]. A negative mammogram may be reassuring but should 
not be considered proof that a woman does not have breast cancer.
Supplemental screening whole-breast ultrasound
No randomized controlled trials demonstrating mortality reduction in women who receive 
supplemental screening ultrasound exist. Data on supplemental screening ultrasound (US) in 
non-high risk women with dense breasts and negative mammography is limited. Using the 
ICER review and the American College of Radiology Imaging Network 6666 trial data, the 
best estimate of the incremental cancer detection rate (iCDR) in women at increased risk 
with a negative mammogram is approximately 2–3 / 1000 [3, 36]. But, the recall rate for 
additional imaging or follow-up imaging is at least 20% (twice that of mammography), and 
the positive predictive value of findings biopsied (PPV3) is approximately 6–8% (compared 
with 25–35% for mammography) [3]. Additionally, the biopsy rate is approximately triple 
that of mammography. Smaller studies suggest the iCDR of US in women with dense 
breasts and average risk is much lower, 1–2/1000 and PPV3 5–6% [2, 37]. This decrease in 
iCDR and PPV is to be expected given the decreased prevalence of disease in an average-
risk group relative to women at high risk. Outcome models estimate that screening 
mammography may prevent 6 breast cancer deaths per 1000 women whereas supplemental 
ultrasound in women with negative mammography and dense breasts would prevent only an 
additional 0.36 deaths per 1000 [26].
Studies evaluating automated whole breast ultrasound are quite limited; however, initial 
reports suggest the cancer detection and predictive value is similar to standard hand-held 
ultrasound [3].
Supplemental screening MRI
Adjunctive screening MRI in women with negative mammograms has consistently been 
shown to be beneficial in women at high risk for breast cancer and is recommended by many 
leading societies including the ACS and NCCN for those with a known germline mutation in 
BRCA1/2, history of chest wall radiation before age 30, or a > 20–25% lifetime risk for 
breast cancer based on family history [8,9]. There is limited data on the use of supplemental 
MRI in women of low or average risk with dense breasts. However, using the numbers 
postulated from the ICER review, the iCDR in high-risk women is approximately 8 / 1000 
and the positive predictive value for findings undergoing biopsy (PPV3) based on screening 
MRI is approximately 22–48% [3]. MRI is preferred over US for supplemental adjunctive 
screening in women of sufficiently high risk as it has a higher iCDR and a lower false 
positive rate than US [38]. Further, supplemental US does not improve the iCDR in women 
undergoing supplemental screening MRI [38].
Potential harms of Screening
The use of additional screening modalities among women with dense breasts would also 
incur harms, including cost, unnecessary recalls and biopsies, overdiagnosis / overtreatment, 
and possibly additional radiation. Screening ultrasound has a higher recall, biopsy, and false 
positive rate than mammography, which would create a significant public health burden if 
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used among the nearly 50% of women with mammographically dense breasts. Supplemental 
ultrasound is not cost-effective [26] and is not covered by many insurance companies, 
potentially exacerbating disparities in screening utilization and outcomes. Although studies 
have consistently shown that when MRI is limited to a high-risk population, the benefit of 
improved cancer detection outweighs the increased false positives, [3] MRI is expensive, 
prohibitive for patients with claustrophobia, and associated with the rare risks of contrast 
reactions and nephrogenic systemic fibrosis [39]. In addition, all screening modalities carry 
the risk of over-diagnosis, defined as the detection of a cancer by screening that would not 
have caused symptoms or death.
Evidence-Based Consensus Management Algorithm for Supplemental 
Screening
Risk Assessment
The Massachusetts legislation recommends a woman with mammographically determined 
dense breasts have a discussion with her primary care provider [29]. Similar to the 
California Breast Density Information Group (CDBIG) recommendations, MA-BREAST 
coalition supports a risk stratification approach for density notification that takes all of the 
patient’s risk factors into account [11]. The risk assessment will determine if the patient 
should be referred for genetic counseling, considered for chemoprevention or prophylactic 
mastectomy, as well as inform the need for supplemental screening. Several prediction 
models exist to assess the probability of BRCA1/2 mutation or the probability of developing 
breast cancer, although all are imperfect and are particularly limited for non-white women 
[40] (Table 1). The ACS and the NCCN both suggest screening breast MRI for women with 
a greater than 20% lifetime risk of breast cancer based primarily on family history [8–9]. 
The ACS has approved the use of BRCAPRO, Tyrer-Cuzick and Claus models to determine 
eligibility for MRI, and specifically states not to use the Gail model for MRI determination, 
as it includes minimal family history [9]. NCCN guidelines for MRI are similar, and also 
include the BOADICEA model [8]. Although the Gail model is not recommended for 
determining the need for MRI, it is most widely accessible to patients and providers and 
may be an important first step in increasing the adoption of risk assessment in primary care 
if used to direct women to further counseling and in depth risk assessment. Currently, only a 
fraction of eligible women undergo screening MRI, suggesting that more widespread risk 
assessment is indicated [43].
Risk Stratified Supplemental Screening Algorithm
If a patient is eligible for genetic testing, she should be referred to a high-risk program or 
clinician for further risk stratification, for determination of the best screening and prevention 
approach.
For women NOT eligible for genetic testing (Figure 2), the following algorithm is supported 
by evidence and multiple national societies (Table 2):
If a patient is low risk (<15% lifetime), regardless of density—The patient should 
continue routine screening mammography. No supplemental screening is recommended 
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given the lack of evidence-based benefit of supplemental screening in low / average risk 
women balanced with the known high rate of false positives. However, in women with 
dense breasts, digital mammography is preferred over film/screen mammography. And early 
clinical data suggests that screening mammography with tomosynthesis may be preferred if 
available for women with dense breasts.
If a patient is high risk (>=20–25% lifetime by models based on family history), 
regardless of density—Adjunctive MRI should be added to routine mammography. If 
the patient is unable to receive MRI (gadolinium allergy, implantable device such as 
pacemaker, severe claustrophobia unresponsive to pre-medication, etc.), then supplemental 
screening ultrasound in addition to routine mammography is recommended.
If a patient is intermediate risk (>=15% and <20% lifetime)—The patient should 
discuss with her primary care provider the risks and benefits of supplemental screening. This 
risk group has insufficient evidence to recommend for or against supplemental screening. 
The ACR / Society of Breast Imaging appropriateness criteria state that MRI in intermediate 
risk women (demarcated as women with 15%–20% lifetime risk of breast cancer) is given a 
7 out of 9 on the ACR guidelines appropriateness scale and may be appropriate for selected 
patients(10)
Screening US in this group is listed as 5 out of 9. NCCN guidelines recommend screening 
mammography without supplemental screening in this group. If the finding of dense breasts 
in the setting of other risk factors would increase a woman’s lifetime risk of breast cancer to 
15–20%, then supplemental screening could be considered after discussion regarding the 
risks of false positives and insurance issues.
Future
Our suggested algorithm is fluid because evidence continues to emerge regarding density, 
supplemental screening, risk stratification, and systems of care.
Additional promising screening modalities
Digital Breast Tomosynthesis (DBT)—Accumulating evidence demonstrates screening 
DBT reduces the recall rate relative to mammography while simultaneously increasing 
cancer detection [48]. Data suggest DBT minimizes the masking phenomenon from dense 
breasts [23–24]. The rapid clinical adoption of DBT may make DBT screening the standard 
in the future.
Dual-energy contrast-enhanced spectral mammography (CESM)—Using 
iodinated intravenous contrast, CESM could become a faster, cheaper and more widely 
available alternative to supplemental screening MRI. In the diagnostic setting, CESM has 
been shown to detect nearly all invasive cancers with fewer false positives than MRI [49].
Scintimammography (MIBI)—Scintimammography increases cancer detection when 
used as supplemental screening in dense breasts as the radiotracer uptake is independent 
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from mammographic density. Investigative techniques are emerging to reduce the radiation 
dose to a low level acceptable for widespread supplemental screening.
Fast MRI—An accelerated 3-minute screening protocol (as opposed to 20–45 minutes for a 
standard breast MRI) has been shown to be effective in women of mild to moderate risk of 
breast cancer. In an initial study of women with dense breasts and negative mammography 
and screening ultrasound, the negative predictive value of the Fast MRI was 99.8% and the 
incremental cancer detection rate was 18.3/1000 [50].
Risk Assessment Strategies
Multiple common and rare genomic variants have been identified that are associated with 
breast cancer risk. Although many of the currently known variants have yet to significantly 
improve breast cancer risk prediction, sequencing improvements will likely lead to a 
growing set of validated markers and the eventual inclusion of whole exome or even whole 
genome information in breast cancer risk prediction models. Furthermore, new methods for 
automated assessment of digital and 3D breast density and other imaging characteristics are 
being developed and may lead to substantial improvements in risk assessment in the near 
future.
Systems of Care
Health information technology offers an important opportunity to go beyond a “one size fits 
all” approach to density notification to more nuanced guidance and education about personal 
risk, risk reduction and screening. Perhaps most important, systems of care need to be held 
accountable for ensuring that women get the right test at the right time. Risk assessment 
algorithms need to be embedded into electronic health records, and updated with the 
availability of new evidence, so that decision support and reminders for providers are 
coordinated across the system.
Conclusion
We provide an evidence-based algorithm for risk stratification for breast cancer 
supplemental screening to address the concerns of patients, primary care providers, and 
radiologists that arise from breast density notification legislation. It is our hope that this may 
serve to educate patients and referrers, improve communication between a patient and her 
physician, and provide an outline to practice effective cost-efficient evidence-based 
medicine. In a letter from the authors of the BI-RADS, 5th edition, Drs. Carl D’Orsi and Ed 
Sickles state that: “the intent of BI-RADS density classification is simply to inform women 
with dense breasts that mammography is not as sensitive for depicting small breast cancers 
as it is for women with fatty breasts. It was not our intent to imply that all women with 
dense breasts, especially women with heterogeneously dense breasts, require supplementary 
screening with either ultrasound or MRI (personal communication 10/22/14 at 17:00).”
More attention needs to be directed toward systematic endeavors to ensure that women, 
primary care providers and radiologists are hearing and conveying consistent information. 
Legislation that has led to individual patient breast density notification may serve as an 
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opportunity to align the recommendations of primary providers, radiologists, and payors 
limiting confusion and possible liability. If the legislation creates better infrastructure for all 
stakeholders to collaborate, this could be a positive unanticipated benefit.
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Figure 1. 
Evidence-Based Suggested Algorithm for Use of Supplemental Screening
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Figure 2. 
Mammographic density inter-and intra-reader variability. A single medio-lateral oblique 
view normal mammogram in a 52 year old patient shows mammographic density that may 
be called heterogeneously dense (“dense”) by some radiologists and scatted fibroglandular 
tissue (“not dense”) by others, causing this patient and her provider to be confused if she 
receives density notification some years and not others.
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Table 2
Major evidence based reviews, panels, or societal recommendations for screening modalities based on risk 
subgroups in women without known genetic mutations
Digital Mammography 
recommended (over Film) in 
women with dense breasts
High Risk (>=20%) recommend 
Mammography + adjunctive MRI
Low Risk (<15%) and dense breasts NO 
supplemental screening routinely recommended
National Comprehensive Cancer 
Network (NCCN) (8)
American Cancer Society (ACS) (9) Cochrane Review (7)
CTAF* panel (4) NCCN (8) CTAF panel (4)
CEPAC** panel (5) American College of Radiology (ACR) (10) CEPAC panel (5)
Society of Breast Imaging (SBI) (ACR) (10) United States Preventive Task Force (USPSTF) 
(44)
American Society of Breast Surgery (ASBS) (45) NCCN (8)
European Society of Breast Imaging (46) American College of Obstetrics and Gynecology 
(ACOG) (47)
ACR (10)
SBI (ACR) (10)
American Cancer Society (ACS) (9)
*CTAF = California Technology Assessment Forum
**CEPAC = New England Comparative Effectiveness Public Advisory Council
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